430 related articles for article (PubMed ID: 29030361)
1. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Mariette X; Förger F; Abraham B; Flynn AD; Moltó A; Flipo RM; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Helmer E; Wang M; Chakravarty EF
Ann Rheum Dis; 2018 Feb; 77(2):228-233. PubMed ID: 29030361
[TBL] [Abstract][Full Text] [Related]
2. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.
Clowse ME; Förger F; Hwang C; Thorp J; Dolhain RJ; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Toublanc N; Wang M; Hale TW
Ann Rheum Dis; 2017 Nov; 76(11):1890-1896. PubMed ID: 28814432
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F; Zbinden A; Villiger PM
Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
[TBL] [Abstract][Full Text] [Related]
5. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
6. Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol.
Smeraglia J; Silva JP; Jones K
Bioanalysis; 2017 Aug; 9(16):1217-1226. PubMed ID: 28705025
[TBL] [Abstract][Full Text] [Related]
7. A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
Ito S; Ishikawa H; Kato R
Mod Rheumatol Case Rep; 2022 Jan; 6(1):6-9. PubMed ID: 34477867
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
Clowse ME; Wolf DC; Förger F; Cush JJ; Golembesky A; Shaughnessy L; De Cuyper D; Mahadevan U
J Rheumatol; 2015 Dec; 42(12):2270-8. PubMed ID: 26523031
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.
Prieto-Peña D; Calderón-Goercke M; Adán A; Chamorro-López L; Maíz-Alonso O; De Dios-Jiménez Aberásturi JR; Veroz R; Blanco S; Martín-Santos JM; Navarro F; Gallego A; González-Suárez S; Conesa A; García-Valle A; Cordero-Coma M; Pardiñas-Barón N; Demetrio R; Calvo-Río V; Martínez-Taboada VM; Castañeda S; Hernández JL; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(1):105-114. PubMed ID: 33124565
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
11. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
12. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
13. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Paul S; Marotte H; Kavanaugh A; Goupille P; Kvien TK; de Longueville M; Mulleman D; Sandborn WJ; Vande Casteele N
Clin Transl Sci; 2020 Jul; 13(4):743-751. PubMed ID: 32100960
[TBL] [Abstract][Full Text] [Related]
14. Six months multicentre pilot open label single-arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA® e-Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients.
Borrás-Blasco J; Vicente-Escrig E; Rodríguez-Lucena FJ; García-Monsalve A; Arroyo-Domingo E; Ferrando-Piqueres R; Casterá E; Navarro-Ruiz A
J Clin Pharm Ther; 2022 Dec; 47(12):2345-2349. PubMed ID: 36470844
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
[TBL] [Abstract][Full Text] [Related]
16. [Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance].
Kameda H; Nishida K; Nannki T; Watanabe A; Oshima Y; Momohara S
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):196-205. PubMed ID: 28747607
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
[TBL] [Abstract][Full Text] [Related]
19. PET/CT Imaging of Human TNFα Using [
Beckford-Vera DR; Gonzalez-Junca A; Janneck JS; Huynh TL; Blecha JE; Seo Y; Li X; VanBrocklin HF; Franc BL
Mol Imaging Biol; 2020 Feb; 22(1):105-114. PubMed ID: 31065895
[TBL] [Abstract][Full Text] [Related]
20. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
